In this issue:
Predicting acute cardiac events after RT for breast cancer
Cholesterol-lowering medications: improved DFS in BIG 1-98
Letrozole vs anastrozole: similar efficacy, toxicity profiles
Residual cancer burden: prognostic significance after neoadjuvant chemotherapy
Prophylactic therapy fails to prevent trastuzumab-induced cardiotoxicity
AI vs tamoxifen cardiotoxicity in postmenopausal breast cancer
Neoadjuvant RT before mastectomy: good long-term survival
Adding celecoxib to neoadjuvant therapy: no benefit in HER2– disease
Adjuvant chemotherapy ± trastuzumab: DFS in pT1abN0 HER2+ disease
Alternative chromosome 17 probes: no clinical utility
Please login below to download this issue (PDF)